

Amendments to the Claims:

The following listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently Amended) A method of ameliorating chronic allograft rejection in a human or animal allograft recipient comprising administering to the recipient in need of such treatment, in combination, a therapeutically effective amount of cyclosporin at least once weekly and a therapeutically effective amount of 2-chlorodeoxyadenosine at least once weekly, wherein the administration produces a decrease in cell-mediated immune responses including decreased circulating levels of CD8+ T cells in the peripheral circulation.
2. (Original) The method according to claim 1 wherein the therapeutically effective amount of cyclosporin is between about seven and about 224 times the amount by mass of 2-chlorodeoxyadenosine.
3. (Original) The method according to claim 1 wherein the therapeutically effective amount of cyclosporin is between about 1 mg and about 16 mg per kilogram of recipient body mass per day.
4. (Original) The method according to claim 3 wherein the dosing regime for cyclosporin is between about 7 and about 112 mg per kilogram of recipient body mass per week.
5. (Original) The method according to claim 4 wherein the dosing regime for cyclosporin is about 5 mg per kilogram of recipient body mass per day for about two weeks followed by about 5 mg per kilogram of recipient body mass about three times per week.
6. (Original) The method according to claim 5 wherein the daily dose is divided into two equal daily doses.
7. (Previously Presented) The method according to claim 1 wherein the therapeutically effective amount of 2-chlorodeoxyadenosine is between about 0.5 mg and about 3 mg per kilogram of recipient body mass per week.

8. (Previously Presented) The method according to claim 1 wherein the therapeutically effective amount of 2-chlorodeoxyadenosine is 1 mg per kilogram of recipient body mass per week.

9. (Original) The method according to claim 7 wherein the dosing regime for 2-chlorodeoxyadenosine is 1 mg per kilogram of recipient body mass per week.

10. (Previously Presented) The method according to claim 7 wherein the dosing regime for 2-chlorodeoxyadenosine is about 3 mg per kilogram of recipient body mass about every three weeks.

11. (Original) The method according to claim 7 wherein the dosing regime for 2-chlorodeoxyadenosine is 1.5 mg per kilogram of recipient body mass about every three weeks.

12. (Original) The method according to claim 1 wherein the mode of administration of cyclosporin and 2-chlorodeoxyadenosine is subcutaneously, orally, or intravenously.

13. (Currently Amended) A method of treating preventing chronic allograft rejection in an allograft recipient comprising administering to an allograft recipient a pharma therapeutically effective amount about one to about 16 milligrams of cyclosporin per kilogram of recipient body mass per day at least once weekly and a therapeutically effective amount about 0.5 to about 3 milligrams of 2-chlorodeoxyadenosine per kilogram of recipient body mass per week. at least once weekly, wherein the administration produces a decrease in cell mediated immune responses including decreased levels of CD8+ T cells in the peripheral circulation.

14. (Currently Amended) The method according to claim 13 wherein the therapeutically effective amount of cyclosporin is present in an amount by weight that is between about 2 and about 224 times the amount by weight of 2-chlorodeoxyadenosine.

15. Cancelled.

16. (Original) The method according to claim 13 wherein the dosing regime for cyclosporin is between about 7 and about 112 mg per kilogram of recipient body mass per week.

17. (Original) The method according to claim 16 wherein the dosing regime for cyclosporin is about 5 mg per kilogram of recipient body mass per day for about two weeks followed by about 5 mg per kilogram of recipient body mass about three times per week.

18. (Original) The method according to claim 17 wherein the daily dose is divided into two equal daily doses.

19. Cancelled.

20. (Currently Amended) The method according to claim 13 wherein the dosing regime for therapeutically effective amount of 2-chlorodeoxyadenosine is 1 mg per kilogram of recipient body mass per week.

21. Cancelled.

22. (Currently Amended) The method according to claim 13 [20] wherein the dosing regime for 2-chlorodeoxyadenosine is about 1.5 to about 3 mg per kilogram of recipient body mass per about three weeks.

23. Cancelled.

24. (Original) The method according to claim 13 wherein the mode of administration of cyclosporin and 2-chlorodeoxyadenosine is subcutaneously, orally, or intravenously.